table network network 2
demonstrated suggested inconclusive safety concern ongoing study display ongoing demontrated benefit only
COVID-19 severe or critically
COVID 19 outpatients
neutralizing antibody
amubarvimab/romlusevimab (BRII-196 and BRII-198-Brii Biosciences) ACTIV-2 ...
bamlanivimab monotherapy OPTIMISE-C19 ... BLAZE-1 phase 2 ...
bamlanivimab/etesevimab BLAZE-4 BLAZE-1 phase 2 ... OPTIMISE-C19 ... BLAZE-1 phase 3 ...
Bebtelovimab (LY-CoV1404) BLAZE 4 LY-CoV1404
casirivimab/imdevimab (Ronapreve) Cov-2067 Weinreich ... Cov-2069 ... Mazzotta
cilgavimab and tixagevimab (Evusheld) TACKLE
regdanvimab (Regkirona- CT-P59-Celltrion) CT-P59 3.2 part 2 CT-P59 3.2 part 1
sotrovimab (Xevudy; VIR-7831) COMET-ICE

3 studies excluded by filtering options 1

6708 Webb, 2021 0130selection pending
6920 Rainwater-Lovett, 2021 0130selection pending
6921 Bariola, 2021 1130not a RCTrisk of bias not avaialble

 

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons